Scientist at Cancer Institute Resigning in Part Over Grant to A&M

SAN ANTONIO (AP) _ An $8 million grant to a drug start-up on the Texas A&M University campus raised questions from an outgoing Nobel laureate at the state’s recently embattled $3 billion cancer research initiative.

The Cancer Prevention and Research Institute of Texas declined comment Friday on internal documents that revealed allegations of politics and eroding scientific standards tainting the funding process.

Making those claims is Dr. Alfred Gilman, the agency’s chief scientific officer who is resigning in protest. Among his concerns was a March grant to Kalon Biotherapeutics in College Station.

Gilman claimed Kalon received peer reviews that were “significantly poorer” than most. He also questioned the award’s timing.

Kalon CEO Andrew Strong said the firm is developing cancer drugs for clinical trials. He said the grant application went through rigorous review.

Texas A&M University System spokesman Steve Moore told WTAW News “We are very proud of the fact that Kalon did win a $7.9 million dollar award from CPRIT, but have no comment on the criteria for selection or selection process used by CPRIT. “

More News